Legend Biotech Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted Net Income: $63 million, with expectations to maintain profitability in the second half of 2026.

Total Revenue: Increased 52% year-over-year to approximately $657 million, driven by strong demand for CARVYKTI.

Gross Margin: Improved to 58%, up from 41% in Q1 2026, with expectations of variability in future quarters.

Operating Margin: Achieved a positive 15%, marking the first quarter of profitability on both IFRS and adjusted basis.

Cash Position: Approximately $965 million in cash, cash equivalents, and time deposits, bolstered by a recent equity offering that raised $212 million.

2Strategic Updates and Business Highlights

Leadership Transition: Alan Bash has been appointed as Interim CEO following the departure of Dr. Ying Huang, with a commitment to continuity in strategy.

CARVYKTI Performance: The CAR-T therapy continues to lead the market, with global sales growth of 50% year-over-year and significant adoption in earlier lines of therapy.

Pipeline Developments: Progress in the in vivo CAR-T platform, including promising early data for LB2501 and LB2102, with plans for IND submissions and further clinical updates.

Market Expansion: CARVYKTI is now available in 348 global treatment sites, with ongoing efforts to penetrate earlier treatment lines.

3Forward Guidance and Outlook

Profitability Goals: The company aims to achieve adjusted net income profitability for the remainder of 2026.

Sales Projections: CARVYKTI is projected to exceed $5 billion in peak annual sales potential, supported by ongoing commercial execution and pipeline advancements.

Clinical Development: Anticipated IND filing for LB2501 by year-end, with further data presentations planned for upcoming medical conferences.

4Bad News, Challenges, or Points of Concern

Market Competition: Increased competition from bispecific therapies, particularly from J&J's TECVAYLI/TALVEY, which may impact CARVYKTI's market position.

Gross Margin Variability: Future gross margins may fluctuate due to changes in outpatient treatment dynamics, which could affect profitability.

Tax Implications: The company expects a tax rate in the high 20% range, which could impact net income projections moving forward.

5Notable Q&A Insights

CEO Search: The Board is conducting a thorough search for a permanent CEO, focusing on long-term leadership qualities.

In Vivo Development: The company plans to advance LB2501 independently while remaining open to partnerships for broader in vivo CAR-T development.

MRD as an Endpoint: Discussions are ongoing with the FDA regarding the use of MRD (minimal residual disease) as a potential surrogate endpoint for CAR-T therapies, particularly for CARTITUDE-6.

Market Dynamics: KOL feedback indicates a preference for sequencing CAR-T therapy before other treatment options, emphasizing CARVYKTI's unique value proposition. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, and notable concerns discussed during the earnings call, providing a balanced view of Legend Biotech's current standing and future outlook.